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ABSTRACT
The 12th Biennial Ovarian Cancer Research Symposium 
organized by the Rivkin Center for Ovarian Cancer and 
the American Association for Cancer Research held on 
September 13–15, 2018 covered cutting edge and relevant 
research topics in ovarian cancer biology and therapy. 
Sessions included detection and prevention, genomics 
and molecular mechanisms, tumor microenvironment and 
immunology, novel therapeutics, and an education session. 
In this article we provide an overview of the key findings 
presented in the tumor microenvironment and immunology 
session.
InTROduCTIOn
Ovarian cancer is the most lethal gynecologic malig-
nancy and the fifth leading cause of cancer-related 
deaths among women in the USA.1 2 Recent devel-
opments in the field of ovarian cancer biology have 
uncovered several key findings that help us under-
stand the disease better and provide us with new 
directions for improving patient outcome.3 Tumor 
microenvironment (TME) has emerged as an impor-
tant area of interest. The TME includes the blood 
vessels, fibroblasts, immune cells, extracellular matrix 
(ECM), and all the signaling molecules surrounding 
the tumor.4 TME closely interacts with the tumor 
and mediates its initiation, progression, and metas-
tasis.4–6 The vital TME components have become new 
therapeutic targets since they can profoundly affect 
patients’ responses to treatments.7 Accumulating 
evidence suggests that the efficacy of chemotherapy 
and the promising technique of immunotherapy can be 
improved through the modulation of TME.8 Therefore, 
research interest in understanding the complexity and 
diversity of TME has exponentially increased in recent 
years. This aspect of ovarian cancer research was 
well represented in the ‘Tumor Microenvironment and 
Immunology of Ovarian Cancer’ session of the 12th 
Biennial Ovarian Cancer Research Symposium.
TumOR mICROenvIROnmenT And ImmunOlOgy 
SeSSIOn
The session included two invited speaker presenta-
tions followed by eight talks from selected abstracts. 
The first invited talk by dr Frances Balkwill from 
Barts Cancer Institute presented her laboratory's 
efforts to better understand ovarian cancer metas-
tasis by first deconstructing metastasis in patient 
tumors and then developing experimental models 
based on the knowledge gained to accurately study 
the mechanism of regulation of metastatic coloniza-
tion of the omentum. Using biopsies of metastasis 
from high-grade serous ovarian cancer (HGSOC) 
patients representing a spectrum of disease progres-
sion from marginal to aggressive, they profiled the 
dynamic interactions and changes in the tumor 
and stroma as the metastasis progressed. Exten-
sive studies were performed using the same biopsy 
samples including gene expression, matrisome, ECM 
organization, biomechanical properties, cytokine/
chemokine levels, and cellular profiles. The matri-
some in humans consists of about 300 proteins that 
form the ECM, growth factors associated with the 
ECM, proteases and other ECM-modifying enzymes, 
and other ECM-associated proteins.9 Changes in the 
matrisome was a key feature identified, which could 
be correlated with prognosis and immune cell signa-
tures that can themselves affect patient outcome. 
Through the reorganization of fibrillar collagens and 
the expression of glycoproteins and proteoglycans, 
the matrisome signature also determined the stiff-
ness of the tumors. Moreover, there was a strong 
association between the number of α-smooth muscle 
actin and α-fibroblast-activated protein (FAP)-positive 
cancer associated fibroblasts (CAFs) and metastasis 
progression. Combining multiple different types of 
analysis on the same biopsies, and utilizing biopsies 
from patients exhibiting different extents of meta-
static tumor progression, Dr Balkwill’s group provided 
a comprehensive picture of the process. This compli-
ments the data from primary tumors provided by The 
Cancer Genome Atlas Program and can effectively 
form a platform for launching detailed studies deci-
phering the mechanism of metastatic progression in 
HGSOC as well as provide novel therapeutic targets to 
treat metastasis.
Dr Balkwill proceeded to describe her group’s 
efforts to reconstruct the omentum in a petri dish to 
provide effective models to further study the mecha-
nisms of the key factors identified by their multi-pa-
rameter analysis of ovarian cancer metastasis. Using 
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HGSOC cells, fibroblasts, and adipocytes embedded in a collagen I 
gel, her group has developed tri-cultures representing the omental 
metastasis. Similarly, they have generated a quadri-culture model 
by including omental mesothelial cells. These models have been 
characterized for the expression of the matrix proteins identified 
in the deconstruction experiments, and transforming growth factor 
beta (TGF-β) was found to be a regulator of five of the six matrix 
molecules identified in the matrisome signature. Dr Balkwill also 
presented their characterization of mouse HGSOC models and 
presented data pointing towards the similarities in the ECM and 
immune subsets in the mouse and human tumors. Taken together, 
the models presented provide unique opportunities to study detailed 
mechanisms of metastatic colonization as well as drug discovery.
In the next invited talk, dr ernst lengyel from the University of 
Chicago reported his group’s recent findings on the role of cancer/
testis antigen 45 (CT45) in increasing chemosensitivity of ovarian 
tumors. To study the role of the metastatic tumor proteome on 
the HGSOC patient outcome following chemotherapy, his group 
collaborated with Matthias Mann from the Max Planck Institute 
of Biochemistry. They developed a high-sensitivity, label-free 
proteomic mass spectrometry-based work-flow to analyze the 
proteome from formalin-fixed paraffin-embedded (FFPE) tumors. 
Using this approach they quantified more than 9000 proteins in 
chemosensitive and chemoresistant tumors. CT45 was the most 
upregulated in the chemosensitive tumors. It was found to affect 
DNA damage repair pathways by regulating protein phosphatase 
4. The expression of CT45 is suppressed in the normal ovary by 
DNA methylation and is significantly upregulated in ovarian tumors 
through the loss of methylation. By combining immunopeptidomics 
and mass spectrometry, Dr Lengyel identified the role of CT45 as 
a cancer antigen presented on human leucocyte antigen class I 
receptors. These CT45 peptides were found to be potent in acti-
vating patient-derived cytotoxic T cells and inducing cancer cell 
killing. This novel comprehensive proteomics strategy incorporating 
proteome quantification, phosphoproteomics, interactome studies, 
and immunopeptidomics was effective in analyzing achieved FFPE 
tumor samples and identifying a unique biomarker, which is partic-
ularly relevant to long-term patient survival and immunotherapy.
Dr Lengyel also described the reciprocal signaling between CAFs 
and ovarian cancer cells identified by quantitative label-free mass 
spectrometry-based phosphoproteomics in co-cultures of CAFs 
and ovarian cancer cells. His group had previously shown that the 
metastasizing ovarian cancer cells utilized lipids released from 
the adipocytes in the omentum to drive their growth. His present 
findings demonstrate that the reciprocal signaling between CAFs 
and the cancer cells help the cancer cells switch their metabo-
lism towards utilizing glycogen once the fat reserves are depleted. 
The activation of p38 mitogen-activated protein kinase signaling in 
the CAFs by the cancer cells resulted in the increased secretion of 
the cytokines interleukin 6 (IL-6), C-X-C motif chemokine ligand 10 
(CXCL10), and C-C motif chemokine ligand 5 (CCL5). The secreted 
cytokines activated glycogenolysis in the cancer cells in a paracrine 
manner by activating phosphoglucomutase 1. Glycogen phosphor-
ylase inhibition reduced metastasis in mice indicating that blocking 
glycogen mobilization could be a potentially effective therapeutic 
strategy to treat metastasis.
dr laurie Ailles from the University of Toronto presented her 
group’s recent findings on the differential gene expression profiles 
of ovarian cancer CAFs and cancer cells. CAFs could be subdivided 
into two groups based on the expression levels of FAP. FAP high and 
FAP low CAFs had distinct transcriptional programs, and analysis 
of The Cancer Genome Atlas data demonstrated a shorter progres-
sion-free and overall survival in FAP high patients. FAP high CAFs 
were functionally distinct from FAP low CAFs, with the FAP high 
CAFs having a greater ability to promote cancer cell invasion in 
vitro and tumor growth in mice. It would be interesting to analyze 
the matrisome signature described by Dr Balkwill in these FAP high 
and FAP low CAFs. The heterogeneity and potential functions of the 
subsets of CAFs would be relevant in future strategies involving 
targeting of the tumor stroma. dr Katherine Fuh from Washington 
University presented her group’s findings on the role of discoidin 
domain receptor 2 (DDR2) expression in fibroblasts in promoting 
ovarian cancer metastasis. Inhibition or silencing DDR2 in fibro-
blasts decreased cancer invasion and mesothelial cell clearance 
as well as decreased collagen staining (trichrome) intensity and 
quantity in tumors. This suggests the possibility of targeting the 
stromal DDR2 as a potential therapeutic option, and again calls 
for the analysis of the secretome of the fibroblasts and the cancer 
cells regulated by DDR2. dr Sara Zanivan from the University of 
Glasgow reported the role of oxidoreductase chloride intracellular 
channel protein 3 (CLIC3) as a secreted factor and key contributor 
of tumor-stromal interaction. Through the mass spectrometry-pro-
teomic comparative analysis of CAFs and their normal counterparts, 
CLIC3 was identified as the most upregulated and the most depos-
ited in ECM. Further analysis revealed that the abundant CLIC3 in 
tumors was secreted by both stromal and cancer cells and could 
activate tissue transgutaminase-2 to promote blood vessel growth 
and increase tumor invasiveness. Their findings suggest a new 
mechanism of TME factor-mediated tumor invasion.
Understanding the complexity and diversity of immune cells 
in the TME has become critical for maximizing the clinical bene-
fits from immunotherapy. dr Alan d’Andrea’s group at Harvard 
Medical School applied a novel high-multiplex tissue cyclic immu-
nofluorescence (t-CycIF) platform to understanding the dynamics 
between DNA damage in cancer cells and the immune context in 
HGSOC TME. This platform quantifies the expression of 60 antigens 
at single cell resolution. Data from over 106 cells showed distinct 
cell compositions in the TME of BRCA1/2 mutant and homologous 
recombination wild-type HGSOCs. On one hand, tumors with high 
programmed cell death protein 1 (PD-1) and its ligand (PD-L1) 
expression have high infiltration of CD1c+dendritic cells, which 
indicates the suppression of antigen presenting pathway and that 
these tumors are likely to respond to immune checkpoint blockade. 
Conversely, a subset of tumors with high levels of DNA damage show 
active interferon signaling and high CD8+ cytotoxic T-cell infiltration 
suggesting an immunogenic phenotype in this subset of HGSOCs. 
The application of new technologies like t-CycIF will contribute to 
the development of rational combination therapies and predictive 
biomarkers for DNA damaging agents and immune checkpoint 
blockade. dr Pamela Kreeger’s group at the University of Wiscon-
sin-Madison analyzed the secretome of macrophages and identified 
fms-related tyrosine kinase 3 ligand, heparin-binding epidermal 
growth factor, IL-6, IL-8, and leptin to be associated with tumor 
spheroid spreading in a macrophage-HGSOC spheroid co-culture 
using a 35-cytokine-multiplex assay. Although each ovarian cancer 
cell line (eg, OVCAR3, OVCA433, and OV90) responded to a different 
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set of cytokines secreted by macrophages, they utilized a common 
signaling pathway to regulate spheroid spreading, which is the 
Janus kinase 2/signal transducers and activators of transcription 
3 (JAK2/STAT3) activation leading to matrix metallopeptidase-9 
(MMP-9)-promoted tumor spreading. These findings suggest that 
multiple macrophage-secreted factors drive the tumor metastasis 
in HGSOC patients. However, they may share the same downstream 
signaling pathways, such as JAK2/STAT3/MMP-9. The identification 
of this molecular mechanism indicates the possibility of controlling 
tumor metastasis in a broad group of patients by targeting the main 
common signaling pathways for macrophage-tumor interaction. dr 
Ronny drapkin’s group at the University of Pennsylvania revealed 
the role of ring finger protein 20 (RNF20)/histone H2B monoubiq-
uitylation (H2Bub1) loss as an early event in HGSOC that modulate 
the immune signaling pathways during tumor initiation. H2Bub1 is 
an epigenetic regulator and tumor suppressor that is lost in serous 
tubal intraepithelial carcinomas (STICs) and HGSOCs. Ubiquitin 
ligase RNF20 catalyzes H2Bub1. Their data demonstrated that the 
inhibition of RNF20 altered immune signaling pathways and led to 
increased cell migration and clonogenic growth. The loss of RNF20/
H2Bub1 functions is possibly responsible for the early oncogenic 
phenotype in STICs.
Angiogenesis is another important therapeutic target in the 
TME. dr Anil Sood’s group in the University of Texas MD Anderson 
Cancer Center identified a new target for overcoming the resistance 
to anti-angiogenic therapy. p130cas (Crk-associated substrate) 
is a central regulator of focal adhesion kinase (FAK)/Src-medi-
ated angiogenesis. Their data showed that p130cas was highly 
expressed in the tumor-associated vascular endothelium. Ablation 
of p130cas gene or inhibition of its expression in mouse models of 
ovarian cancer increased the sensitivity to anti-vascular endothe-
lial growth factor antibody treatment and inhibited tumor growth 
through autophagy-regulated cell death in endothelial cells. They 
have generated nanoparticle-delivered peptide antagonist to 
p130cas as a targeted therapeutic agent. The antagonist’s clinical 
efficacy and mechanism of action are under evaluation.
It is also very exciting that new imaging technologies have been 
applied to the quantitative assessment of the architectural features 
in the TME of ovarian cancer. dr Paul Campagnola’s group at the 
University of Wisconsin-Madison used collagen-specific sensitive 
second harmonic generation imaging microscopy, 3D texture anal-
ysis, and machine learning to extract textural features and build 
models of the ECM in the ovarian cancer TME. They generated 
models for normal stroma, high-risk stroma, benign tumor, high-
grade serous, low-grade serous, and endometroid carcinoma. By 
examining the collagen alterations, they developed quantitative 
biomarkers for assessing the increased collagen concentration and 
the changes of alignment of collagen molecules within fibrils and 
fibers. Their data indicate that combining macro/supramolecular 
probes and the fiber morphology classification improves our under-
standing of TME evolution in ovarian cancer and the role of ECM 
alteration in disease etiology. This novel approach has the potential 
to be developed into new prognostic and diagnostic methods.
The poster session included very interesting presentations 
covering epigenetic modulators, non-coding RNAs, tumor immu-
nology, in vitro models, cancer stem cells, novel therapeutics, and 
so on. Coffman reported that ovarian cancer cells mediate EZH2 
induction and epigenetic reprogramming to convert mesenchymal 
stem cells into carcinoma-associated mesenchymal stem cells. 
Zhang demonstrated that a combination of histone deacetylase 
6 inhibition with PD-L1 checkpoint blockade could be a potential 
strategy to treat ARID1A-mutated clear cell ovarian cancer. Inhi-
bition of nuclear factor-κB activity in macrophages and potentially 
other cells in the ovarian TME was shown to inhibit tumor progres-
sion by Yull. Other studies included association of decreased let-7 
with stemness, the role of long non-coding RNAs in metabolism, 
autophagy, or immune response, and a glycosylation-dependent 
mechanism involving Sox2 that drives a cancer stem cell pheno-
type. Posters covering tumor immunology demonstrated that the 
inositol-requiring enzyme 1/X box binding protein 1 arm of the 
endoplasmic reticulum stress response pathway in dendritic cells 
was necessary for accelerated ovarian cancer progression, that 
neuropilin-1 promotes survival and suppressive function of T
reg
, and 
included a study providing new insights into the metabolic path-
ways that regulate T cell anti-tumor responses in ovarian cancer. 
Another study demonstrated that ovarian cancer patient monocytes 
are more tumoricidal when cultured with interferons than mono-
cytes from matched controls, supporting a novel, innate, immune-
based approach to immunotherapy of ovarian cancer.
In vitro models were represented by a 3D cell culture model for 
predicting the response to standard carbo-taxol chemotherapy, 
a 3D perfused bioreactor that allows the study of tumor biology 
and anti-tumor drug testing under physiological conditions, and 
models mimicking shear forces to improve our fundamental 
understanding of peritoneal metastasis and mechanotransduc-
tion. Therapeutics targeting ovarian cancer included the use of 
myxoma virus (MYXV) as a poxvirus that synergized with chemo-
therapy, aldehyde dehydrogenase 1A inhibitors increased LKB1 
phosphorylation leading to AMP-activated protein kinase a phos-
phorylation. McLean showed that the combination of inhibiting 
IL-6/LIF signaling with ruxolitinib with anti-estrogen therapy 
resulted in a synergistic decrease in ovarian cancer tumor cell 
viability. A new two-step targeting approach was presented 
that introduces non-natural targets (azide functional groups) in 
the tumors followed by the delivery of drug-loaded polymeric 
nanoparticles that are surface modified to have high affinity for 
these synthetic targets. Other pathways covered in the abstract 
session included apelin/APJ pathway in omental metastasis, role 
of TGFβ1/protein kinase Cα/Twist1 signaling pathway in ovarian 
cancer metastasis, and the induction of insulin-like growth factor 
signaling by follicular fluid in fimbrial cells causing stemness, 
clonal expansion, and transformation. Yang-Hartwich presented 
data supporting the role of mutant p53 in promoting the initiation 
of HGSOC from fallopian tube precursors, while Rankin demon-
strated that tumor-associated mesothelial cells promoted tumor 
invasion by increasing collagen deposition and remodeling.
COnCluSIOnS
The TME contributes to the ‘hallmarks’ of cancer and also shapes 
therapeutic responses and chemoresistance.4 6 10 It provides 
potential prognostic markers and therapeutic opportunities. 
Significant advances have been made in our understanding 
of the various components of the TME, including the cellular 
and acellular constituents. The 12th Biennial Ovarian Cancer 
Research Symposium reflected the increasing interest in the 
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TME of ovarian cancer and provided an excellent overview of 
the cutting-edge research going on in the ovarian cancer TME 
field, which provides renewed hope for our collective efforts to 
understand and eventually cure ovarian cancer. The identifica-
tion of targetable molecular and cellular components in the TME 
will lead to the development of combination therapies that can 
simultaneously modulate TME and eliminate cancer cells to treat 
ovarian cancer more efficiently and effectively.11 The new break-
throughs in the field of ovarian cancer TME that were presented 
at this meeting are leading the way in our fight against this 
deadly disease.
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